REVELATION BIOSCIENCES, INC. Earnings Per Share (Basic)
REVELATION BIOSCIENCES, INC. (REVB) reported Earnings Per Share (Basic) of -$0.87 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-06
- REVELATION BIOSCIENCES, INC. earnings per share, basic for the quarter ending 2026-06-30 was -$0.87.
- REVELATION BIOSCIENCES, INC. earnings per share, basic for the quarter ending 2026-03-31 was -$2.71.
- REVELATION BIOSCIENCES, INC. earnings per share, basic for the quarter ending 2025-12-31 was $1.91, a 93.84% decline year-over-year.
- REVELATION BIOSCIENCES, INC. earnings per share, basic for the quarter ending 2025-09-30 was -$1.77.
- REVELATION BIOSCIENCES, INC. earnings per share, basic for fiscal 2025 was -$23.95.
- REVELATION BIOSCIENCES, INC. earnings per share, basic for fiscal 2024 was -$1052.16.
- REVELATION BIOSCIENCES, INC. earnings per share, basic for fiscal 2023 was -$8.44.
- REVELATION BIOSCIENCES, INC. earnings per share, basic for fiscal 2022 was -$149.20.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 6 month as first filed | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 9 month as first filed | Earnings Per Share, Basic 12 month | Earnings Per Share, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$0.87 10-Q · filed 2026-08-06 | -$3.41 10-Q · filed 2026-08-06 | -$7.61 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$9.18 derived: net income ÷ weighted average shares · filed 2026-08-06 | ||||
| 2026-03-31 | -$2.71 10-Q · filed 2026-05-07 | -$11.83 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$10.50 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$18.15 derived: net income ÷ weighted average shares · filed 2026-08-06 | ||||
| 2025-12-31 | $1.91 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$10.80 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$25.10 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$23.95 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | -$1.77 10-Q · filed 2025-11-06 | -$7.24 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$9.76 10-Q · filed 2025-11-06 | -$19.62 derived: net income ÷ weighted average shares · filed 2026-08-06 | ||||
| 2025-06-30 | -$28.04 10-Q · filed 2026-08-06 | -$7.01 10-Q · filed 2025-08-08 | -$54.39 10-Q · filed 2026-08-06 | -$13.60 10-Q · filed 2025-08-08 | -$124.83 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$165.28 derived: net income ÷ weighted average shares · filed 2026-08-06 | ||
| 2025-03-31 | -$25.34 10-Q · filed 2026-05-07 | -$2.11 10-Q · filed 2025-05-08 | -$298.46 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$222.52 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$500.25 derived: net income ÷ weighted average shares · filed 2026-05-07 | |||
| 2024-12-31 | $31.02 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$40073.58 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$1081.90 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$1052.16 10-K · filed 2026-02-26 | -$87.68 10-K · filed 2025-03-06 | |||
| 2024-09-30 | -$40.15 10-Q · filed 2025-11-06 | -$0.84 10-Q · filed 2024-11-08 | -$236.52 derived: net income ÷ weighted average shares · filed 2025-11-06 | -$354.05 10-Q · filed 2025-11-06 | -$7.38 10-Q · filed 2024-11-08 | |||
| 2024-06-30 | -$246.27 10-Q · filed 2025-08-08 | -$5.13 10-Q · filed 2024-08-09 | -$390.02 10-Q · filed 2025-08-08 | -$8.13 10-Q · filed 2024-08-09 | ||||
| 2024-03-31 | -$39.37 10-Q · filed 2025-05-08 | -$2.46 10-Q · filed 2024-05-10 | ||||||
| 2023-12-31 | -$8.44 10-K · filed 2025-03-06 | -$0.53 10-K · filed 2024-03-22 | ||||||
| 2023-09-30 | -$9.94 10-Q · filed 2024-11-08 | -$0.42 10-Q · filed 2023-11-09 | $9.62 10-Q · filed 2024-11-08 | $0.43 10-Q · filed 2023-11-09 | ||||
| 2023-06-30 | -$5.83 10-Q/A · filed 2024-09-23 | -$0.25 10-Q · filed 2023-08-11 | $24.52 10-Q/A · filed 2024-09-23 | $1.61 10-Q · filed 2023-08-11 | ||||
| 2023-03-31 | $45.52 10-Q/A · filed 2024-09-23 | $2.79 10-Q · filed 2023-05-22 | ||||||
| 2022-12-31 | -$149.20 10-K/A · filed 2024-09-23 | -$20.09 10-K · filed 2023-03-30 | ||||||
| 2022-09-30 | -$1.91 10-Q · filed 2023-11-09 | -$0.06 10-Q · filed 2022-11-10 | -$19.61 10-Q · filed 2023-11-09 | -$0.57 10-Q · filed 2022-11-10 | ||||
| 2022-06-30 | -$4.16 10-Q · filed 2023-08-11 | -$0.12 10-Q · filed 2022-08-15 | -$19.71 10-Q · filed 2023-08-11 | -$0.58 10-Q · filed 2022-08-15 | ||||
| 2022-03-31 | -$15.90 10-Q · filed 2023-05-22 | |||||||
| 2021-12-31 | -$0.00 derived: net income ÷ weighted average shares · filed 2023-03-30 | $0.01 derived: net income ÷ weighted average shares · filed 2023-03-30 | $0.00 derived: net income ÷ weighted average shares · filed 2023-03-30 | -$42.50 10-K · filed 2023-03-30 | -$1.17 10-K · filed 2022-04-15 | |||
| 2021-09-30 | -$0.48 10-Q · filed 2022-11-10 | $0.00 derived: net income ÷ weighted average shares · filed 2022-11-10 | -$3.83 10-Q · filed 2022-11-10 | |||||
| 2021-06-30 | -$0.39 10-Q · filed 2022-08-15 | -$1.61 10-Q · filed 2022-08-15 | ||||||
| 2020-12-31 | -$0.68 10-K · filed 2022-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |